Judge Scraps Rule Eliminating Medical Debt on Credit Reports
The Consumer Financial Protection Bureau finalized the rule in early January, shortly before President Trump took office. The bureau estimated that the rule, which prohibited credit bureaus from including medical debt in the reports and scores sent to lenders, would have removed $49 billion in medical bills from the credit reports of 15 million Americans. Credit reports are used by lenders to make decisions about whether to approve loans for homes, cars and small businesses.
Before the rule took effect, two trade groups credit bureaus and credit reporting agencies sued to block it, arguing that the bureau had exceeded its authority. They filed the lawsuit in the U.S. District Court for the Eastern District of Texas, a popular venue for litigation challenging the federal government's reach.
Under the Biden administration, the agency fought the lawsuit, but once Mr. Trump returned to the White House, the new leaders he installed to oversee the consumer bureau reversed course. In April, the bureau joined the trade groups in asking the federal court to strike down the agency's regulation.
Last Friday, the court granted their request. Judge Sean D. Jordan wrote that he agreed with the trade groups' argument that the consumer bureau's rule conflicted with Fair Credit Reporting Act, which governs consumer credit reports. That federal law allows lenders and credit reporting agencies to use financial information related to medical debts, and the bureau exceeded its authority by 'fashioning a new regulatory scheme that conflicts with the plain text' of the existing law, the judge wrote.
The Consumer Data Industry Association, a plaintiff in the lawsuit to block the rule, praised the judge's decision. 'Information about unpaid medical debts is an important element in assessing a consumer's ability to pay. This is the right outcome for protecting the integrity of the system,' said Dan Smith, the group's chief executive.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate
Kentucky Gov. Andy Beshear speaks during the Semafor World Economy Summit 2025 at Conrad Washington on April 23, 2025 in Washington, DC. () LINCOLN — Kentucky Gov. Andy Beshear is coming to Nebraska to speak to Democrats for the state party's top annual fundraising event in November. Beshear is a Democratic governor in a deeply red Republican state. He and other 2028 potential presidential hopefuls visited South Carolina in recent weeks, to test the water for their campaign messages. He was picked to lead the Democratic Governors Association into next year's midterm elections and has been touted as 'most popular Democratic governor in America.' Beshear was attorney general of Kentucky before becoming governor in 2019. His father was previously governor. National Democrats have been seeking answers as President Donald Trump made gains among working-class voters, including minority voters, last year. A trend of prominent Democratic figures making their way to the heartland has emerged, and some are crossing the Missouri River from traditionally first-in-the-nation Iowa into Nebraska. Independent U.S. Sen. Bernie Sanders launched his 'Fighting Oligarchy' nationwide tour in Omaha. Minnesota Gov. Tim Walz hosted a Democratic town hall earlier this year And Former Texas U.S. Rep. Beto O'Rourke is having a similar town hall in Omaha next month. The events with prominent Democratic figures appear aimed at energizing the Nebraska Democratic base for the midterms and come when two federal races could be competitive. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Nebraska's 2nd Congressional District has drawn national attention as its single presidential race electoral vote has swung from Republicans to Democrats in recent years, most recently to former Vice President Kamala Harris in 2024. Nebraska could regain the national spotlight in 2026, with an open seat race in the state's 2nd District for the U.S. House and Dan Osborn's nonpartisan Senate bid against Republican U.S. Sen. Pete Ricketts. Both races could determine which party controls what parts of Congress. But Nebraska Democrats face an uphill battle in a state where Republicans outnumber Democrats about 2 to 1, Republicans have gained a legislative supermajority, and the party last held a congressional seat with former U.S. Rep. Brad Ashford in 2017. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
17 minutes ago
- Yahoo
Columbia University agrees to pay more than $220M in deal with Trump to restore federal funding
NEW YORK (AP) — Columbia University has reached a deal with the Trump administration to pay more than $220 million to the federal government to restore federal research money that was canceled in the name of combating antisemitism on campus, the university announced Wednesday. Under the agreement, the Ivy League school will pay a $200 million settlement over three years, the university said. It will also pay $21 million to settle investigations brought by the U.S. Equal Employment Opportunity Commission. 'This agreement marks an important step forward after a period of sustained federal scrutiny and institutional uncertainty," acting University President Claire Shipman said. The Trump administration pulled the funding, because of what it described as the university's failure to squelch antisemitism on campus during the Israel-Hamas war that began in October 2023. Columbia then agreed to a series of demands laid out by the Republican administration, including overhauling the university's student disciplinary process and adopting a new definition of antisemitism. Wednesday's agreement — which does not include an admission of wrongdoing — codifies those reforms while preserving the university's autonomy, Shipman said. The school had been threatened with the potential loss of billions of dollars in government support, including more than $400 million in grants cancelled earlier this year. 'The settlement was carefully crafted to protect the values that define us and allow our essential research partnership with the federal government to get back on track," Shipman said. "Importantly, it safeguards our independence, a critical condition for academic excellence and scholarly exploration, work that is vital to the public interest.' As part of the deal, Columbia agreed to a series of changes previously announced in March, including reviewing its Middle East curriculum to make sure it was 'comprehensive and balanced' and appointing new faculty to its Institute for Israel and Jewish Studies. It also promised to end programs 'that promote unlawful efforts to achieve race-based outcomes, quotes, diversity targets or similar efforts.' The university will also have to issue a report to a monitor assuring that its programs 'do not promote unlawful DEI goals.' The pact comes after months of uncertainty and fraught negotiations at the more than 270-year-old university. It was among the first targets of President Donald Trump's crackdown on pro-Palestinian campus protests and on colleges that he asserts have allowed Jewish students be threatened and harassed. Columbia's own antisemitism task force found last summer that Jewish students had faced verbal abuse, ostracism and classroom humiliation during the spring 2024 demonstrations. Other Jewish students took part in the protests, however, and protest leaders maintain they aren't targeting Jews but rather criticizing the Israeli government and its war in Gaza. Columbia's leadership — a revolving door of three interim presidents in the last year — has declared that the campus climate needs to change. Also in the settlement is an agreement to ask prospective international students 'questions designed to elicit their reasons for wishing to study in the United States,' and establishes processes to make sure all students are committed to 'civil discourse.' Solve the daily Crossword
Yahoo
17 minutes ago
- Yahoo
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the 'Existing Warrants') to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements which were filed and declared effective by the Securities and Exchange Commission (the 'SEC'). The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $3.9 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the 'Replacement Warrants') to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act'). The Replacement Warrants will be exercisable, beginning on the effective date of stockholder approval, into an aggregate of up to 8,637,810 shares of common stock, at an exercise price of $0.9047 per share, and a term of exercise equal to five years from the date of shareholder approval. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The Replacement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Replacement Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Forward Looking Statements This communication contains 'forward-looking' statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected closing of the offering. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company's Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas 908-824-0775PALI@
